The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma.
 
Robyn Saw
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Amgen
Travel, Accommodations, Expenses - Amgen
 
Alexander M. Menzies
Honoraria - Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - MSD Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Alexander Guminski
Consulting or Advisory Role - Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Merck; Novartis; Pfizer
 
Omgo E Nieweg
No Relationships to Disclose
 
Kerwin F. Shannon
No Relationships to Disclose
 
Maria Gonzalez
No Relationships to Disclose
 
Sydney Ch'ng
No Relationships to Disclose
 
Richard Kefford
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Speakers' Bureau - GlaxoSmithKline; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
John F Thompson
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Provectus
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline; Provectus
 
Jonathan Stretch
No Relationships to Disclose
 
Andrew J Spillane
No Relationships to Disclose
 
Richard A Scolyer
No Relationships to Disclose
 
Georgina V. Long
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MERCK; Novartis; Provectus; Roche/Genentech
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche/Genentech